Citation Information :
Khera D, Toteja N, Singh S, Singh S, Kumar P, Sharma P, Singh K. Is There a Role of Presepsin as a Novel Biomarker in Pediatric Sepsis?. Indian J Crit Care Med 2022; 26 (6):712-716.
Background: Sepsis in children is a conundrum of diagnostic and therapeutic challenges. There is an exigent need for a novel biomarker that can serve as a clear distinguisher of sepsis from other non-septic inflammatory conditions. The role of presepsin as a biomarker of sepsis in children is still a matter of scientific inquiry.
Aim and objectives: To evaluate the diagnostic accuracy of presepsin for the prediction of septic shock, in children aged 1 month to 18 years.
Materials and methods: This prospective cohort study was conducted in the pediatric emergency, ward, and intensive care unit of a tertiary care hospital. We enrolled all consecutive admissions aged 1 month to 18 years with a diagnosis of sepsis and compared the presepsin, procalcitonin, and C-reactive protein (CRP) levels on admission (day 1) and 72 hours later (day 4) with the clinical outcomes.
Results: The mean (±SD) presepsin values in blood culture-proven sepsis patients at admission and 72 hours later were 609.77 ± 417.30 and 839 ± 748.07, respectively. The procalcitonin and presepsin levels at 72 hours in sepsis patients with shock were significantly elevated (38.2 ± 45.55 and 1129.1 ± 1133.80, respectively) as compared to those without shock (10.7 ± 25.42 and 472.5 ± 507.81, respectively), p <0.05. The receiver operating characteristic (ROC) curve analysis of presepsin at 72 hours had an area under curve (AUC) of 0.730, suggesting a fair diagnostic accuracy.
Conclusion: Elevated presepsin levels may indicate greater severity of sepsis, particularly in those with shock. However, it lacks diagnostic ability early in the disease and has limited prognostic potential in predicting mortality.
Dien Bard J, McElvania TeKippe E. Diagnosis of bloodstream infections in children. J Clin Microbiol 2016;54(6):1418–1424. DOI: 10.1128/JCM.02919-15.
Faix JD. Established and novel biomarkers of sepsis. Biomark Med 2011;5(2):117–130. DOI: 10.2217/bmm.11.21.
Galliera E, Massaccesi L, de Vecchi E, Banfi G, Romanelli MMC. Clinical application of presepsin as diagnostic biomarker of infection: overview and updates. Clin Chem Lab Med 2019;58(1):11–17. DOI: 10.1515/cclm-2019-0643.
Wu C-C, Lan H-M, Han S-T, Chaou C-H, Yeh C-F, Liu S-H, et al. Comparison of diagnostic accuracy in sepsis between presepsin, procalcitonin, and C-reactive protein: a systematic review and meta-analysis. Ann Intensive Care 2017;7(1):91. DOI: 10.1186/s13613-017-0316-z.
Matics TJ, Sanchez-Pinto LN. Adaptation and validation of a pediatric sequential organ failure assessment score and evaluation of the sepsis-3 definitions in critically ill children. JAMA Pediatr 2017;171(10):e172352. DOI: 10.1001/jamapediatrics.2017.2352.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315(8):801–810. DOI: 10.1001/jama.2016.0287.
Masson S, Caironi P, Fanizza C, Thomae R, Bernasconi R, Noto A, et al. Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial. Intensive Care Med 2015;41(1):12–20. DOI: 10.1007/s00134-014-3514-2.
Markanday A. Acute phase reactants in infections: evidence-based review and a guide for clinicians. Open Forum Infect Dis 2015;2(3):ofv098. DOI: 10.1093/ofid/ofv098.
Chenevier-Gobeaux C, Borderie D, Weiss N, Mallet-Coste T, Claessens Y-E. Presepsin (sCD14-ST), an innate immune response marker in sepsis. Clin Chim Acta 2015;450:97–103. DOI: 10.1016/j.cca.2015.06.026.
Bellos I, Fitrou G, Pergialiotis V, Thomakos N, Perrea DN, Daskalakis G. The diagnostic accuracy of presepsin in neonatal sepsis: a meta-analysis. Eur J Pediatr 2018;177(5):625–632. DOI: 10.1007/s00431-018-3114-1.
Yoon SH, Kim EH, Kim HY, Ahn JG. Presepsin as a diagnostic marker of sepsis in children and adolescents: a systemic review and meta-analysis. BMC Infect Dis 2019;19(1):760. DOI: 10.1186/s12879-019-4397-1.
Tanır Basaranoglu S, Karadag-Oncel E, Aykac K, Ozsurekci Y, Aycan AE, Cengiz AB, et al. Presepsin: a new marker of catheter related blood stream infections in pediatric patients. J Infect Chemother 2018;24(1):25–30. DOI: 10.1016/j.jiac.2017.08.012.
Plesko M, Suvada J, Makohusova M, Waczulikova I, Behulova D, Vasilenkova A, et al. The role of CRP, PCT, IL-6and presepsin in early diagnosis of bacterial infectious complications in paediatric haemato-oncological patients. Neoplasma 2016;63(5):752–760. DOI: 10.4149/neo_2016_512.
Ghazy M, El-Halaby H, El-Sabbagh A, Shaltout A. Diagnostic and prognostic values of soluble CD14 (presepsin) in sepsis in pediatric intensive-care patients. Alex J Pediatr 2018;31(3):141. DOI: 10.4103/AJOP.AJOP_32_18.
Olad E, Sedighi I, Mehrvar A, Tashvighi M, Fallahazad V, Hedayatiasl A, et al. Presepsin (scd14) as a marker of serious bacterial infections in chemotherapy induced severe neutropenia. Iran J Pediatr 2014;24(6):715–722. PMID: 26019777.
Baraka A, Zakaria M. Presepsin as a diagnostic marker of bacterial infections in febrile neutropenic pediatric patients with hematological malignancies. Int J Hematol 2018;108(2):184–191. DOI: 10.1007/s12185-018-2447-x.
Urbonas V, Eidukaitė A, Tamulienė I. The predictive value of soluble biomarkers (CD14 subtype, interleukin-2 receptor, human leucocyte antigen-G) and procalcitonin in the detection of bacteremia and sepsis in pediatric oncology patients with chemotherapy-induced febrile neutropenia. Cytokine 2013;62(1):34–37. DOI: 10.1016/j.cyto.2013.02.030.
Algebaly HA, Fouad HM, Elkholy MM, Ibrahim SK, Riad NM. Is presepsin a reliable marker of sepsis diagnosis in pediatric intensive care unit? Open Access Macedonian J Med Sci 2020;8(B):66–70. DOI: 10.3889/oamjms.2020.3431.
Shozushima T, Takahashi G, Matsumoto N, Kojika M, Endo S, Okamura Y. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother 2011;17(6):764–769. DOI: 10.1007/s10156-011-0254-x.
Romualdo LG de G, Torrella PE, González MV, Sánchez RJ, Holgado AH, Freire AO, et al. Diagnostic accuracy of presepsin (soluble CD14 subtype) for prediction of bacteremia in patients with systemic inflammatory response syndrome in the Emergency Department. Clin Biochem 2014;47(7–8):505–508. DOI: 10.1016/j.clinbiochem.2014.02.011.
Klouche K, Cristol JP, Devin J, Gilles V, Kuster N, Larcher R, et al. Diagnostic and prognostic value of soluble CD14 subtype (Presepsin) for sepsis and community-acquired pneumonia in ICU patients. Ann Intensive Care 2016;6(1):59. DOI: 10.1186/s13613-016-0160-6.
Brodska H, Valenta J, Pelinkova K, Stach Z, Sachl R, Balik M, et al. Diagnostic and prognostic value of presepsin vs. established biomarkers in critically ill patients with sepsis or systemic inflammatory response syndrome. Clin Chem Lab Med 2018;56(4):658–668. DOI: 10.1515/cclm-2017-0839.
Yamamoto T, Nishimura T, Kaga S, Uchida K, Tachibana Y, Esaki M, et al. Diagnostic accuracy of presepsin for sepsis by the new Sepsis-3 definitions. Am J Emerg Med 2019;37(10):1936–1941. DOI: 10.1016/j.ajem.2019.01.025.